ATTENTION/WARNING - NE PAS DÉPOSER ICI/DO NOT SUBMIT HERE

Ceci est la version de TEST de DIAL.mem. Veuillez ne pas soumettre votre mémoire sur ce site mais bien à l'URL suivante: 'https://thesis.dial.uclouvain.be'.
This is the TEST version of DIAL.mem. Please use the following URL to submit your master thesis: 'https://thesis.dial.uclouvain.be'.
 

Clinical use of checkpoint inhibitors for resected stage III and IV metastatic cutaneous melanoma: current situation and future prospects

Laoudj, Anefal
(2021)

Files

LAOUDJ_Anefal_75331600_2020-2021.pdf
  • UCLouvain restricted access
  • Adobe PDF
  • 2.78 MB

Details

Supervisors
Coulie, Pierre ; Baurain, Jean-François
Faculty
Faculté de pharmacie et des sciences biomédicales
Degree label
Master [120] en sciences pharmaceutiques, à finalité spécialisée
Abstract
Metastatic melanoma is a rare but deadly skin cancer with an increasing incidence rate worldwide. Checkpoint blockade revolutionized the prognosis of metastatic melanoma patients and raised hopes for remission and prolonged survival. The principle of checkpoint immunotherapy is to unleash the patient's own immune defence to fight cancer cells. Numerous randomized controlled phase 3 trials studied the efficacy of this treatment providing promising results. However, more progress remains to be made, regarding their side effects, apparition of resistance after the therapy, and patient who do not respond at all to the therapy. Thereby, checkpoint inhibitor immunotherapy continues to be a vast area of research, with efforts focused on improving their effectiveness, reducing their toxicity, finding effective combinations and looking for new therapeutic targets.